NASDAQ : ORKA
Oruka Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 96.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.41B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.28B |
| Enterprise Value | 5.16B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 66.21M |
| Shares Outstanding | 66.21M |
| Shares Change (YoY) | +49.96% |
| Shares Change (QoQ) | +13.96% |
| Owned by Insiders (%) | 2.21% |
| Owned by Institutions (%) | 101.26% |
| Float | 56.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.32 |
| P/TBV Ratio | 5.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 38.51 |
| Quick Ratio | 38.03 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -18.23% |
| Return on Assets (ROA) | -12.95% |
| Return on Invested Capital (ROIC) | -13.25% |
| Return on Capital Employed (ROCE) | -13.89% |
| Weighted Average Cost of Capital (WACC) | 3.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.11 |
| 52-Week Price Change | +237.24% |
| 50-Day Moving Average | 88.21 |
| 200-Day Moving Average | 69.55 |
| Relative Strength Index (RSI) | 63.29 |
| Average Volume (20 Days) | 898,142 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.11M |
| Short Previous Month | 7.78M |
| Short % of Shares Out | 9.23% |
| Short % of Float | 10.74% |
| Short Ratio (days to cover) | 5.86 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -155.08M |
| Pretax Income | -132.89M |
| Net Income | -109.69M |
| EBITDA | -154.94M |
| EBIT | -155.08M |
| Earnings Per Share (EPS) | -$2.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 873.56M |
| Total Debt | 2.55M |
| Net Cash | 1.12B |
| Net Cash Per Share | $16.96 |
| Equity (Book Value) | 1.11B |
| Book Value Per Share | 18.20 |
| Working Capital | 861.59M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -100.92M |
| Capital Expenditures | -235,000 |
| Depreciation & Amortization | 134,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -101.15M |
| FCF Per Share | -$1.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -49.96% |
| Shareholder Yield | -49.96% |
| Earnings Yield | -2.13% |
| FCF Yield | -1.61% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $156.17 |
| Price Target Difference | 64.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |